Engineering a patient's own T cells
CAR-T therapy starts by collecting a patient's T cells through leukapheresis. In the lab, the cells are genetically modified, usually with a viral vector, to express a chimeric antigen receptor: a synthetic protein that fuses an antibody-derived recognition domain on the outside with T cell activation signaling domains on the inside. This lets the engineered cell recognize a chosen tumor surface antigen directly, without needing the usual antigen presentation steps.
The modified cells are expanded to large numbers, the patient typically receives lymphodepleting chemotherapy to make room, and the CAR-T cells are reinfused. Inside the body they bind their target antigen, activate, proliferate, and kill antigen-bearing cells. Approved products have notably targeted CD19 and BCMA in certain blood cancers.
Why it works in some cancers and not others
CAR-T has been most successful against certain B cell leukemias, lymphomas, and multiple myeloma, where a uniform surface antigen is available. Solid tumors are harder: antigens are less uniform, the tumor microenvironment is suppressive, and getting the cells to penetrate is difficult. The therapy also carries serious risks, including cytokine release syndrome and neurotoxicity, which require specialized monitoring.
Scope of this explanation
This is general educational information, not medical advice. CAR-T is a complex therapy delivered at specialized centers, and eligibility, products, and outcomes vary by disease and individual. Treatment decisions should be made with a qualified specialist.